[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HN2010000203A - DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME. - Google Patents

DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME.

Info

Publication number
HN2010000203A
HN2010000203A HN2010000203A HN2010000203A HN2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A HN 2010000203 A HN2010000203 A HN 2010000203A
Authority
HN
Honduras
Prior art keywords
compositions
arilamino
methods
sulfonamids
polymorphes
Prior art date
Application number
HN2010000203A
Other languages
Spanish (es)
Inventor
Vernier Jean-Michel
Edward Rowlings Colin
Luc Girardet Jean
Dimock Stuart
Quart Barry
Miner Jeffrey
Original Assignee
Ardea Bioscinences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2010000203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Bioscinences Inc filed Critical Ardea Bioscinences Inc
Publication of HN2010000203A publication Critical patent/HN2010000203A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pest Control & Pesticides (AREA)
  • Urology & Nephrology (AREA)
  • Dentistry (AREA)

Abstract

ESTA INVENCION SE RELACIONA CON COMPUESTOS N-(2 ARILAMINO) ARIL SULFONAMIDA QUE SON INHIBIDORES DE MEK INCLUYENDO FORMAS POLIMORFICAS CRISTALINAS QUE EXHIBEN UN PERFIL DE DIFRACCION DE RAYOS X EN POLVO ESPECIFICO Y/O UN PERFIL QUE COMPRENDEN LOS COMPUESTOS DESCRITOS Y METODOS DE USO DE LOS COMPUESTOS Y COMPOSICIONES DESCRITOS INCLUYENDO EL USO EN EL TRATAMIENTO Y O PREVENCION DE CANCER, ENFERMEDADES HIPERPOROLIFERATIVAS Y CONDICIONES INFLAMATORIAS. LA INVENCION TAMBIEN SE RELACIONA CON METODOS PARA OBTENER LOS COMPUESTOS Y COMPOSICIONES QUE SE DESCRIBEN.THIS INVENTION IS RELATED TO N- (2 ARILAMINO) ARIL SULFONAMIDA COMPOUNDS THAT ARE INHIBITORS OF MEK INCLUDING CRYSTALLINE POLYMORPHIC FORMS THAT DISPLAY A SPECIFIC POWDER X-RAY PROFILE AND / OR A METHOD OF USE THE COMPOUNDS AND COMPOSITIONS DESCRIBED INCLUDING THE USE IN THE TREATMENT AND PREVENTION OF CANCER, HYPERPOROLIFERATIVE DISEASES AND INFLAMMATORY CONDITIONS. THE INVENTION IS ALSO RELATED TO METHODS TO OBTAIN THE COMPOUNDS AND COMPOSITIONS THAT ARE DESCRIBED.

HN2010000203A 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME. HN2010000203A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14

Publications (1)

Publication Number Publication Date
HN2010000203A true HN2010000203A (en) 2012-11-19

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010000203A HN2010000203A (en) 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME.

Country Status (23)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20100092424A (en)
CN (2) CN103479604B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA020624B1 (en)
EC (1) ECSP109910A (en)
HK (1) HK1147396A1 (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2720671A1 (en) * 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
CN102143943B (en) * 2008-09-09 2014-03-12 弗·哈夫曼-拉罗切有限公司 Polymorphs of acyl sulfonamides
RU2579897C2 (en) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Agents linking frizzled receptor and their use
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
JP5767122B2 (en) * 2009-03-11 2015-08-19 アルデア バイオサイエンシズ，インコーポレイティド Combination medicine comprising RDEA119 / BAY869766 for the treatment of certain cancers
KR20120094165A (en) 2009-10-13 2012-08-23 알로스팀 테라퓨틱스 엘엘씨 Novel mek inhibitors, useful in the treatment of diseases
WO2011047788A1 (en) * 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
CA2833390A1 (en) * 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
EA026550B1 (en) * 2011-05-27 2017-04-28 Байер Интеллектчуал Проперти Гмбх Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
AU2013269809B2 (en) * 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
PL2909182T3 (en) * 2012-10-19 2020-06-01 Array Biopharma Inc. Preparation of and formulation comprising a mek inhibitor
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EA201992744A1 (en) * 2017-06-16 2020-05-27 Бета Фарма, Инк. PHARMACEUTICAL COMPOSITIONS N- (2- (2- (DIMETHYLAMINO) ETOXY) -4-METOXY-5 - ((4- (1-METHYL-1H-INDOL-3-IL) PYRIMIDIN-2-IL) AMINO) Phenyl) Acrylamide AND HIS SALTS
BR112021018168B1 (en) 2019-03-21 2023-11-28 Onxeo PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
ES2177868T3 (en) * 1992-08-25 2002-12-16 Searle & Co HYDROXYETHYLAMINOSULPHONAMIDS OF ALPHA- AND BETA-AMINO ACIDS AS INHIBITORS OF RETROVIRIC PROTEASES.
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
ES2249060T3 (en) * 1999-01-13 2006-03-16 Warner-Lambert Company Llc DIARILAMINS REPLACED WITH 1-HETEROCICLE.
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CN100441176C (en) * 2001-09-24 2008-12-10 杰西·L·S·奥 Methods and compositions for determining chemosensitizing doses of suramin for use in combination therapy
KR20050040907A (en) * 2002-07-17 2005-05-03 타이탄 파머슈티컬즈 인코퍼레이티드 Combination of chemotherapeutic drugs for increasing antitumor activity
KR20110102485A (en) * 2002-07-30 2011-09-16 아에테르나 젠타리스 게엠베하 A drug product of alkylphosphocholines in combination with antitumor medicaments
CN101198314A (en) * 2005-04-12 2008-06-11 伊兰制药国际有限公司 Nanoparticulate quinazoline derivative formulations
WO2006115154A1 (en) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
PT1912636E (en) * 2005-07-21 2014-07-24 Ardea Biosciences Inc N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd New crystal of piperacillin sodium-1 hydrate and method for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
CN101808516B (en) 2013-08-28
AU2008282338A1 (en) 2009-02-05
KR20140098185A (en) 2014-08-07
HK1147396A1 (en) 2011-08-12
NZ582929A (en) 2012-03-30
CA2693390C (en) 2017-01-17
EA201400552A1 (en) 2014-09-30
EA032294B1 (en) 2019-05-31
EP2184984A1 (en) 2010-05-19
JP2015078199A (en) 2015-04-23
CO6470808A2 (en) 2012-06-29
MX2010001244A (en) 2010-08-31
KR20100092424A (en) 2010-08-20
JP6309880B2 (en) 2018-04-11
CN103479604B (en) 2016-08-10
AP2817A (en) 2013-12-31
MA31881B1 (en) 2010-12-01
EP2184984A4 (en) 2013-07-24
TN2010000049A1 (en) 2011-09-26
JP2017125021A (en) 2017-07-20
CA2693390A1 (en) 2009-02-05
CR11244A (en) 2010-05-20
PH12015501914A1 (en) 2017-07-31
BRPI0815659A2 (en) 2014-09-30
AU2008282338B2 (en) 2015-02-12
CN103479604A (en) 2014-01-01
EA201000268A1 (en) 2010-08-30
IL203296A (en) 2017-06-29
DOP2010000045A (en) 2010-10-31
AU2015200390B2 (en) 2017-02-23
AP2010005134A0 (en) 2010-02-28
KR20150091434A (en) 2015-08-10
ECSP109910A (en) 2010-04-30
SV2010003469A (en) 2010-04-30
EA020624B1 (en) 2014-12-30
WO2009018233A1 (en) 2009-02-05
CN101808516A (en) 2010-08-18
JP2010535232A (en) 2010-11-18

Similar Documents

Publication Publication Date Title
HN2010000203A (en) DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF PREPARATION USE OF THE SAME.
CR10304A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
ECSP077302A (en) 6H- [1] BENZOPIRANO [4,3-b] CHLNOLINES, AND ITS USE AS A STROGEN AGENT
UY29375A1 (en) 5-ALCOXIALQUIL-6-ALQUIL-7-AMINO-AZOLOPIRIMIDINAS, A PROCEDURE FOR ITS OBTAINING AND THE USE OF THE SAME TO COMBAT HARMFUL FUNGES, AS WELL AS PRODUCTS THAT CONTAIN THEM.
HN2012001162A (en) TRIAZOLOPIRIDINS
CL2011001967A1 (en) Compounds derived from substituted carboxamide-azaheterocyclic, p70s6k inhibitors, preparation process thereof; pharmaceutical composition that includes them; and its use in the treatment of inflammatory diseases and cancer; Pharmaceutical kit
CR20110579A (en) SUBSTITUTED 1-CYANOETHYLETHYCLIC CARBOXAMIDE 750 COMPOUNDS
DOP2006000193A (en) ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS INCLUDING THEM AND METHODS FOR USE
PA8593001A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UY28708A1 (en) REPLACED HETEROCICLES AND USES OF THE SAME
ECSP10010415A (en) NEW COMPOUNDS THAT ARE ERK INHIBITORS
ECSP077268A (en) RAPAMYCIN POLYMORPH II AND THE USES OF THE SAME
GT201000061A (en) DERIVATIVES OF URACILO OR TIMINA FOR THE TREATMENT OF HEPATITIS C
UY30748A1 (en) NEW COMPOUNDS
CR11861A (en) ORGANIC COMPOUNDS
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
CL2019001993A1 (en) Selective inhibitors of jak1.
GT200600199A (en) SULFONAMID DIARILSULPHONES AND THEIR USE
UY29414A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
ECSP099822A (en) POLICYCLE GUANINE DERIVATIVES AND THEIR METHODS OF USE
CO6361849A2 (en) DERIVATIVES OF N-CICLOALQUIL-NBIFENILMETIL-CARBOXAMIDA FUNGICIDAS
UY28670A1 (en) SUBSTITUTED ARILPIRAZOLES
CR11098A (en) PIRIDO COMPOUNDS [2,3-D] PIRIMIDINA-7-ONA AS P13K-ALFA INHIBITORS FOR CANCER TREATMENT
CO2018004572A2 (en) Human plasma kallikrein inhibitors
CR9685A (en) NEW DERIVATIVES OF BENZOHETEROCICLILETILBENZAMIDA